Abstract：
OBJECTIVE: The correlation between fatty acids (FAs) and depression is not yet conclusive. This study examined the relationship of FAs composition with the presence and clinical characteristics of first-diagnosed, drug-naïve patients with depression.
METHODS: A total of 139 first-diagnosed, drug-naïve patients with depression and 55 healthy controls (HCs) were included in the cross-sectional study. The levels of erythrocyte membrane FAs were compared and then the correlation between clinical symptoms and fatty acid levels in depression was investigated.
RESULTS: Compared to HCs, patients with depression had higher C18:1n9t (z = -2.033, p = 0.042), C20:4n6 (z = -2.104, p = 0.035), C20:3n6 (z = -2.104, p = 0.035) and n-6 polyunsaturated fatty acids (PUFAs) (z = -2.127, p = 0.033), whereas the levels of C18:1n9c (z = -3.348, p = 0.001) were significantly lower. Higher C20:3n6, C20:4n6, C18:1n9t and n-6 PUFAs levels were associated with higher severity of depressive and anxiety symptoms in patients with depression, and the correlation remained after adjusting for the related confounding factors (p < 0.05).
CONCLUSIONS: Patients with first-diagnosed, drug-naïve depression show abnormal erythrocyte fatty acid composition. Trans fatty acids (TFAs) and n-6 PUFAs levels are closely related to clinical characteristics of depression. This study indicated that increased n-6 PUFAs and TFAs are characteristic changes of first-diagnosed, drug-naïve depression.
METHODS: A total of 139 first-diagnosed, drug-naïve patients with depression and 55 healthy controls (HCs) were included in the cross-sectional study. The levels of erythrocyte membrane FAs were compared and then the correlation between clinical symptoms and fatty acid levels in depression was investigated.
RESULTS: Compared to HCs, patients with depression had higher C18:1n9t (z = -2.033, p = 0.042), C20:4n6 (z = -2.104, p = 0.035), C20:3n6 (z = -2.104, p = 0.035) and n-6 polyunsaturated fatty acids (PUFAs) (z = -2.127, p = 0.033), whereas the levels of C18:1n9c (z = -3.348, p = 0.001) were significantly lower. Higher C20:3n6, C20:4n6, C18:1n9t and n-6 PUFAs levels were associated with higher severity of depressive and anxiety symptoms in patients with depression, and the correlation remained after adjusting for the related confounding factors (p < 0.05).
CONCLUSIONS: Patients with first-diagnosed, drug-naïve depression show abnormal erythrocyte fatty acid composition. Trans fatty acids (TFAs) and n-6 PUFAs levels are closely related to clinical characteristics of depression. This study indicated that increased n-6 PUFAs and TFAs are characteristic changes of first-diagnosed, drug-naïve depression.
摘要：
目的：脂肪酸（FAs）与抑郁症之间的相关性尚未定论。这项研究检查了FAs组成与首次诊断的存在和临床特征的关系，初治药物的抑郁症患者。
方法：共139例首次诊断，本横断面研究纳入了未接受药物治疗的抑郁症患者和55名健康对照(HCs).比较红细胞膜FAs水平，然后研究抑郁症临床症状与脂肪酸水平之间的相关性。
结果：与HC相比，抑郁症患者的C18：1n9t较高（z=-2.033，p=0.042），C20:4n6(z=-2.104,p=0.035),C20：3n6（z=-2.104，p=0.035）和n-6多不饱和脂肪酸（PUFA）（z=-2.127，p=0.033），而C18：1n9c（z=-3.348，p=0.001）的水平显着降低。较高的C20：3n6，C20：4n6，C18：1n9t和n-6PUFAs水平与抑郁症患者抑郁和焦虑症状的严重程度有关，校正相关混杂因素后，相关性仍然存在(p<0.05)。
结论：首次诊断的患者，药物初治抑郁症显示红细胞脂肪酸组成异常。反式脂肪酸（TFA）和n-6PUFA水平与抑郁症的临床特征密切相关。这项研究表明，n-6PUFA和TFA的增加是首次诊断的特征性变化，药物天真抑郁症。
方法：共139例首次诊断，本横断面研究纳入了未接受药物治疗的抑郁症患者和55名健康对照(HCs).比较红细胞膜FAs水平，然后研究抑郁症临床症状与脂肪酸水平之间的相关性。
结果：与HC相比，抑郁症患者的C18：1n9t较高（z=-2.033，p=0.042），C20:4n6(z=-2.104,p=0.035),C20：3n6（z=-2.104，p=0.035）和n-6多不饱和脂肪酸（PUFA）（z=-2.127，p=0.033），而C18：1n9c（z=-3.348，p=0.001）的水平显着降低。较高的C20：3n6，C20：4n6，C18：1n9t和n-6PUFAs水平与抑郁症患者抑郁和焦虑症状的严重程度有关，校正相关混杂因素后，相关性仍然存在(p<0.05)。
结论：首次诊断的患者，药物初治抑郁症显示红细胞脂肪酸组成异常。反式脂肪酸（TFA）和n-6PUFA水平与抑郁症的临床特征密切相关。这项研究表明，n-6PUFA和TFA的增加是首次诊断的特征性变化，药物天真抑郁症。
